| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Icon Plc$143.84
+0.3 (+0.21%)
B 71Pipeline Score Tools & Services · Commercial
Market Cap
8.16 B
EPS
7.43
P/E Ratio
14.44 $
Value Trade
196.69 M
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
274.28 K
52 Week Range
66.57 - 211.00
% held by Insiders
0.93 %
% held by Institutions
105.46 %
Enterprise Value
11.22 B
Total Shares
80.75 M
Short %
3.74 %
Float Shares
80.34 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
B71
Pipeline Score $15.6B
Pipeline ValueValuation Signal
50
Drugs Scored1.9x
rNPV / MCap Top 95%
Small Cap (rank 46 of 905)
Percentile RankIcon Plc holds a solid B-grade pipeline (71/100), with $24.4B risk-adjusted pipeline value, led by Apabetalone in Diabetes Mellitus, Type 2 (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apabetalone Small molecule | Diabetes Mellitus, Type 2 | Phase 3 | NCT02586155 | 48% | $12.3B | COMPLETED | 2,425 | - | - | Jun 21, 2021 | - | Aug 20, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ICLR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Icon Plc (ICLR) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
ICLR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ICLR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ICLR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ICLR Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ICLR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-ICLR
May 28, 2026ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation
ICON plc reported its financial results for Q4 and full year 2025, highlighting strong net bookings and a positive demand environment. The Audit Committee concluded its investigation into accounting practices, identifying material weaknesses in internal controls. Despite a decrease in earnings per share, ICON anticipates sustainable growth through strategic investments and partnerships.
Read more →-ICLR
May 13, 2026ICON expands US early phase research capabilities with new clinic and outpatient centres
ICON has announced the expansion of its early phase research capabilities in the US by opening new clinic and outpatient centers. This strategic move aims to enhance their service offerings and cater to the growing demand for early phase clinical trials. The expansion reflects ICON's commitment to advancing research in the biopharma sector.
Read more →-ICLR
Feb 12, 2026ICON plc Provides Update on Timing of Fourth Quarter and Full Year 2025 Earnings Results and Investigation into Accounting Practices
ICON plc announced the timing for its fourth quarter and full year 2025 earnings results, expected by April 30, 2026. The company is undergoing an internal investigation into its accounting practices, focusing on revenue recognition from 2023 to 2025. Preliminary findings suggest minor overstatements in revenue, and the company has withdrawn its financial guidance for 2025.
Read more →-ICLR
Jan 27, 2026ICON’s Accellacare Site Network Expands Oncology Research Capabilities With New Cancer Institute Partnership
ICON plc has announced the opening of the Brian Moran Cancer Institute at Duly Health and Care in Illinois, enhancing its Accellacare Site Network's oncology research capabilities. This partnership aims to improve patient access to innovative cancer treatments and address recruitment challenges in oncology trials. The institute features a team of specialized oncologists and surgical specialists.
Read more →Competitive Position
How ICLR ranks across every disease it competes inCompetitive Position is a premium feature
See how ICLR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial